Pfizer ends clinical Trials of DMD drug domagrozumab after disappointing results
Pfizer, the US pharmaceutical giant, has announced the discontinuation of two ongoing clinical trials for its drug domagrozumab (PF-06252616), intended to treat Duchenne muscular dystrophy ... Read More